WS12-4 Long-term safety and efficacy of lumacaftor/ivacaftor therapy in patients aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR mutation (F/F) - Chilvers, M; Davies, JC; Ratjen, F; Milla, C; Owen, CA; Tian, S; Han, Z; Wang, LT (Journal of Cystic Fibrosis, 2019)